Next 10 |
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-genera...
2024-04-02 10:04:00 ET Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years...
2024-03-28 16:59:01 ET More on SCYNEXIS GSK revises Scynexis licensing deal for antifungal agent Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS Financial information for SCYNEXIS Read the full article on Seekin...
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results...
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will pre...
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burd...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Scynexis securities between March 31, 2023 and September 22, 2023 and ...
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generat...
Philadelphia, Pennsylvania--(Newsfile Corp. - January 4, 2024) - Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired SCYNEXIS, Inc. ("Scynexis") (NASDAQ: SCYX) securities. If you suffered lo...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to o...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-genera...
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results...